What does CHROMETRA do?

CHROMETRA is a healthcare practice in Kortenaken. Private Limited, started on 23 November 2015, 1 establishment.

What is the address of CHROMETRA?

The registered office of CHROMETRA is located at Merelnest 3, 3470 Kortenaken.

Is CHROMETRA still active?

Yes. According to the CBE (29 October 2026) CHROMETRA is active, legal situation “Normale toestand”, started on 23 November 2015.

Is CHROMETRA registered on Peppol?

Yes, CHROMETRA is registered on the Peppol network with ID 0208:0643522447.

What is the enterprise number of CHROMETRA?

The enterprise number of CHROMETRA is BE0643522447.

When was CHROMETRA founded?

CHROMETRA was founded on 23 November 2015.

Who are the directors of CHROMETRA?

According to the 2025 annual accounts, the directors of CHROMETRA are: Volker Leen, Nazir Hanna.

Is CHROMETRA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 23 November 2015; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did CHROMETRA make in 2025?

CHROMETRA recorded a loss after taxes of € 22,351 in financial year 2025.

What is the revenue of CHROMETRA?

As a small company, CHROMETRA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -21,760.

CHROMETRA (Private Limited) - Kortenaken - BE0643522447

Dossier CHROMETRA, printed on 29 October 2026 from databakkes.be/en/0643522447/chrometra. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

CHROMETRA from Kortenaken, company number BE0643522447, closed financial year 2025 with a result of € -22,351 after tax. For that financial year CHROMETRA recorded a gross margin of € -21,760 and equity of € 27,854. Compared with financial year 2024, the result moved from € 4,341 to € -22,351. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on October 2, 2026.

What it is worth Healthy

€ 27,854

▼ 45% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -22,351

▼ still € 4,341 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 8,906

▲ 88% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 16,694.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 52,463

▲ 241% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 6,595 Gross margin 2022: € 6,595 First fiscal year in the series	€ 31,927 Gross margin 2023: € 31,927 ▲ € 25,332 vs 2022 (€ 6,595) Favourable step	€ 7,020 Gross margin 2024: € 7,020 ▼ 78% vs 2023 (€ 31,927) Unfavourable step	€ -21,760 Gross margin 2025: € -21,760 ▼ € 28,780 vs 2024 (€ 7,020) Unfavourable step	▼ € 28,780
Profit after taxes	€ 2,503 Profit after taxes 2022: € 2,503 First fiscal year in the series	€ 22,093 Profit after taxes 2023: € 22,093 ▲ € 19,590 vs 2022 (€ 2,503) Favourable step	€ 4,341 Profit after taxes 2024: € 4,341 ▼ 80% vs 2023 (€ 22,093) Unfavourable step	€ -22,351 Profit after taxes 2025: € -22,351 ▼ € 26,693 vs 2024 (€ 4,341) Unfavourable step	▼ € 26,693
Equity	€ 23,772 Equity 2022: € 23,772 First fiscal year in the series	€ 45,864 Equity 2023: € 45,864 ▲ 93% vs 2022 (€ 23,772) Favourable step	€ 50,206 Equity 2024: € 50,206 ▲ 9% vs 2023 (€ 45,864) Favourable step	€ 27,854 Equity 2025: € 27,854 ▼ 45% vs 2024 (€ 50,206) Unfavourable step	▼ 45%
Total debts	€ 16,641 Total debts 2022: € 16,641 First fiscal year in the series	€ 8,674 Total debts 2023: € 8,674 ▼ 48% vs 2022 (€ 16,641) Favourable step	€ 24,629 Total debts 2024: € 24,629 ▲ 184% vs 2023 (€ 8,674) Unfavourable step	€ 69,366 Total debts 2025: € 69,366 ▲ 182% vs 2024 (€ 24,629) Unfavourable step	▲ 182%
Cash	€ 438 Cash 2022: € 438 First fiscal year in the series	€ 12,475 Cash 2023: € 12,475 ▲ € 12,037 vs 2022 (€ 438) Favourable step	€ 4,730 Cash 2024: € 4,730 ▼ 62% vs 2023 (€ 12,475) Unfavourable step	€ 8,906 Cash 2025: € 8,906 ▲ 88% vs 2024 (€ 4,730) Favourable step	▲ 88%
Retained profit	€ 12,612 Retained profit 2022: € 12,612 First fiscal year in the series	€ 34,704 Retained profit 2023: € 34,704 ▲ 175% vs 2022 (€ 12,612) Favourable step	€ 39,046 Retained profit 2024: € 39,046 ▲ 13% vs 2023 (€ 34,704) Favourable step	€ 16,694 Retained profit 2025: € 16,694 ▼ 57% vs 2024 (€ 39,046) Unfavourable step	▼ 57%
Balance sheet total	€ 40,413 Balance sheet total 2022: € 40,413 First fiscal year in the series	€ 54,539 Balance sheet total 2023: € 54,539 ▲ 35% vs 2022 (€ 40,413) Unchanged	€ 74,834 Balance sheet total 2024: € 74,834 ▲ 37% vs 2023 (€ 54,539) Unchanged	€ 97,221 Balance sheet total 2025: € 97,221 ▲ 30% vs 2024 (€ 74,834) Unchanged	▲ 30%

Key figures of CHROMETRA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to CHROMETRA?

What happened at CHROMETRA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Oct 2, 2026 New annual accounts for financial year 2025: loss of € 22,351 (▼ € 26,693 vs 2024). filed late Source: NBB ↗
Nov 23, 2015 New establishment in Kortenaken. KBO
Nov 23, 2015 Start of the company according to the CBE. KBO

In short

From € 2,503 profit in 2022 to € 22,351 loss in 2025.

Paid € 10,002 in corporate taxes since 2022.

Best year ever: 2023, with € 22,093 profit.

Original PDFs at the National Bank ↗

Management

Perseus Biomics 50%

The stake of Perseus Biomics comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

CHROMETRA

Behind CHROMETRA are Volker Leen and Nazir Hanna. The shares are held by Perseus Biomics (50%).

Directors

According to the 2025 annual accounts

Volker Leen

Director

Also active at: Perseus Biomics, Dionis, Chrometra Scientific

Nazir Hanna

Director

Also active at: Perseus Biomics

Shareholders

Perseus Biomics

50%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Merelnest 3

3470 Kortenaken

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.

All companies at this address →

Dionis same network

€ 133,578 gross margin · 2025

Chrometra Scientific same network

€ 7,007 gross margin · 2025

Merelnest

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0643.522.447

VAT number

BE 0643.522.447

Registered office

Merelnest 3, 3470 Kortenaken

Names & denominations

CHROMETRA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

23 November 2015

Peppol

Active · Active since 19 Mar 2026

Activities · NACE

Activiteiten van medische beeldvorming en medische laboratoria

Activiteiten van medische laboratoria

View on CBE Public ↗ Annual accounts (NBB) ↗

CHROMETRA

Financials

What happened to CHROMETRA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions